nach oben

Erschienen in:

09.08.2019 | Review

On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells

verfasst von: Georgios Ntolkeras, Chrysanthi Barba, Athanasios Mavropoulos, Georgios K. Vasileiadis, Efthymios Dardiotis, Lazaros I. Sakkas, Georgios Hadjigeorgiou, Dimitrios P. Bogdanos

Erschienen in: Immunologic Research | Ausgabe 4-5/2019

Einloggen, um Zugang zu erhalten

Abstract

Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and differentiation. Their effects on autoagression have led investigators to assess their clinical significance in autoimmune disease, such as multiple sclerosis (MS), a chronic progressive demyelinating disease of autoimmune nature. The dysregulated immunity noted in MS features a profound shift from Tregs dominance to Th17 cell superiority. In this review, we discuss the immunobiological basis of statins, their role in autoimmunity related to MS, and the data from experimental models and human studies on their effect on Th17 cells.

Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Invest. 2017;127(10):3577–87. https://doi.org/10.1172/JCI90609.CrossRefPubMedPubMedCentral

Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(4). https://doi.org/10.1101/cshperspect.a029025.CrossRefPubMedPubMedCentral

Chang MR, Rosen H, Griffin PR. RORs in autoimmune disease. Curr Top Microbiol Immunol. 2014;378:171–82. https://doi.org/10.1007/978-3-319-05879-5_8.CrossRefPubMed

Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018;87:1–15. https://doi.org/10.1016/j.jaut.2017.12.007.CrossRefPubMed

Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011;12(3):255–63. https://doi.org/10.1038/ni.1993.CrossRefPubMedPubMedCentral

Buehler U, Schulenburg K, Yurugi H, Solman M, Abankwa D, Ulges A, et al. Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity. EMBO J. 2018;37(16). https://doi.org/10.15252/embj.201899429.

Hiltensperger M, Korn T. The interleukin (IL)-23/T helper (Th)17 axis in experimental autoimmune encephalomyelitis and multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(1). https://doi.org/10.1101/cshperspect.a029637.CrossRef

Paroni M, Maltese V, De Simone M, Ranzani V, Larghi P, Fenoglio C, et al. Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. J Allergy Clin Immunol. 2017;140(3):797–808. https://doi.org/10.1016/j.jaci.2016.11.045.CrossRefPubMed

Muls N, Nasr Z, Dang HA, Sindic C, van Pesch V. IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy. PLoS One. 2017;12(3):e0173780. https://doi.org/10.1371/journal.pone.0173780.CrossRefPubMedPubMedCentral

10.

Tahmasebinia F, Pourgholaminejad A. The role of Th17 cells in auto-inflammatory neurological disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;79(Pt B):408–16. https://doi.org/10.1016/j.pnpbp.2017.07.023.CrossRef

11.

Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediat Inflamm. 2017;2017:3908061–11. https://doi.org/10.1155/2017/3908061.CrossRef

12.

Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol. 2008;180(9):6411–20.CrossRefPubMed

13.

Mastorodemos V, Ioannou M, Verginis P. Cell-based modulation of autoimmune responses in multiple sclerosis and experimental autoimmmune encephalomyelitis: therapeutic implications. Neuroimmunomodulation. 2015;22(3):181–95. https://doi.org/10.1159/000362370.CrossRefPubMed

14.

Abdolahi M, Yavari P, Honarvar NM, Bitarafan S, Mahmoudi M, Saboor-Yaraghi AA. Molecular mechanisms of the action of vitamin a in Th17/Treg axis in multiple sclerosis. J Mol Neurosci. 2015;57(4):605–13. https://doi.org/10.1007/s12031-015-0643-1.CrossRefPubMed

15.

Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14(1):117. https://doi.org/10.1186/s12974-017-0892-8.CrossRefPubMedPubMedCentral

16.

Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol. 2009;21(6):612–8. https://doi.org/10.1016/j.coi.2009.09.011.CrossRefPubMedPubMedCentral

17.

Kleinewietfeld M, Hafler DA. Regulatory T cells in autoimmune neuroinflammation. Immunol Rev. 2014;259(1):231–44. https://doi.org/10.1111/imr.12169.CrossRefPubMedPubMedCentral

18.

Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008;29(9):429–35. https://doi.org/10.1016/j.it.2008.06.005.CrossRefPubMed

19.

Sakkas LI, Mavropoulos A, Perricone C, Bogdanos DP. IL-35: a new immunomodulator in autoimmune rheumatic diseases. Immunol Res. 2018;66(3):305–12. https://doi.org/10.1007/s12026-018-8998-3.CrossRefPubMed

20.

Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal. 2011;4(162):ra12. https://doi.org/10.1126/scisignal.2001270.CrossRefPubMed

21.

Hao S, Chen X, Wang F, Shao Q, Liu J, Zhao H, et al. Breast cancer cells-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells. Carcinogenesis. 2018;39:1488–96. https://doi.org/10.1093/carcin/bgy136.CrossRefPubMed

22.

Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19(6):739–46. https://doi.org/10.1038/nm.3179.CrossRefPubMed

23.

Shao TY, Hsu LH, Chien CH, Chiang BL. Novel Foxp3(−) IL-10(−) regulatory T-cells induced by B-cells alleviate intestinal inflammation in vivo. Sci Rep. 2016;6:32415. https://doi.org/10.1038/srep32415.CrossRefPubMedPubMedCentral

24.

Kadowaki A, Miyake S, Saga R, Chiba A, Mochizuki H, Yamamura T. Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3. Nat Commun. 2016;7:11639. https://doi.org/10.1038/ncomms11639.CrossRefPubMedPubMedCentral

25.

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–8. https://doi.org/10.1038/nature04753.CrossRefPubMed

26.

Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9(6):641–9. https://doi.org/10.1038/ni.1610.CrossRefPubMedPubMedCentral

27.

Li L, Kim J, Boussiotis VA. IL-1beta-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol. 2010;185(7):4148–53. https://doi.org/10.4049/jimmunol.1001536.CrossRefPubMed

28.

Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112(6):2340–52. https://doi.org/10.1182/blood-2008-01-133967.CrossRefPubMed

29.

Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood. 2009;113(18):4240–9. https://doi.org/10.1182/blood-2008-10-183251.CrossRefPubMedPubMedCentral

30.

Li L, Boussiotis VA. Molecular and functional heterogeneity of T regulatory cells. Clin Immunol. 2011;141(3):244–52. https://doi.org/10.1016/j.clim.2011.08.011.CrossRefPubMedPubMedCentral

31.

Dombrowski Y, O'Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20(5):674–80. https://doi.org/10.1038/nn.4528.CrossRefPubMedPubMedCentral

32.

Tao Y, Zhang X, Chopra M, Kim MJ, Buch KR, Kong D, et al. The role of endogenous IFN-beta in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol. 2014;192(12):5610–7. https://doi.org/10.4049/jimmunol.1302580.CrossRefPubMed

33.

Sacramento PM, Monteiro C, Dias ASO, Kasahara TM, Ferreira TB, Hygino J, et al. Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4(+) T-cell subsets in multiple sclerosis patients. Eur J Immunol. 2018;48(8):1376–88. https://doi.org/10.1002/eji.201847525.CrossRefPubMed

34.

Lowther DE, Chong DL, Ascough S, Ettorre A, Ingram RJ, Boyton RJ, et al. Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response. Acta Neuropathol. 2013;126(4):501–15. https://doi.org/10.1007/s00401-013-1159-9.CrossRefPubMed

35.

Alvarez-Sanchez N, Cruz-Chamorro I, Diaz-Sanchez M, Lardone PJ, Guerrero JM, Carrillo-Vico A. Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients. Sci Rep. 2019;9(1):2302. https://doi.org/10.1038/s41598-019-38897-w.CrossRefPubMedPubMedCentral

36.

Toker A, Slaney CY, Backstrom BT, Harper JL. Glatiramer acetate treatment directly targets CD11b(+)Ly6G(−) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand J Immunol. 2011;74(3):235–43. https://doi.org/10.1111/j.1365-3083.2011.02575.x.CrossRefPubMed

37.

Rodi M, Dimisianos N, de Lastic AL, Sakellaraki P, Deraos G, Matsoukas J, et al. Regulatory cell populations in relapsing-remitting multiple sclerosiS (RRMS) patients: effect of disease activity and treatment regimens. Int J Mol Sci. 2016;17(9). https://doi.org/10.3390/ijms17091398.CrossRefPubMedCentral

38.

Pant AB, Wang Y, Mielcarz DW, Kasper EJ, Telesford KM, Mishra M, et al. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment. J Neuroimmunol. 2017;303:22–30. https://doi.org/10.1016/j.jneuroim.2016.12.010.CrossRefPubMed

39.

Lee J, Park N, Park JY, Kaplan BLF, Pruett SB, Park JW, et al. Induction of immunosuppressive CD8(+)CD25(+)FOXP3(+) regulatory T cells by suboptimal stimulation with staphylococcal enterotoxin C1. J Immunol. 2018;200(2):669–80. https://doi.org/10.4049/jimmunol.1602109.CrossRefPubMed

40.

Sinha S, Itani FR, Karandikar NJ. Immune regulation of multiple sclerosis by CD8+ T cells. Immunol Res. 2014;59(1–3):254–65. https://doi.org/10.1007/s12026-014-8529-9.CrossRefPubMedPubMedCentral

41.

York NR, Mendoza JP, Ortega SB, Benagh A, Tyler AF, Firan M, et al. Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun. 2010;35(1):33–44. https://doi.org/10.1016/j.jaut.2010.01.003.CrossRefPubMedPubMedCentral

42.

Deiss A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother. 2013;13(3):313–35. https://doi.org/10.1586/ern.13.17.CrossRefPubMed

43.

Havrdova E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287–95. https://doi.org/10.1007/s00415-016-8128-x.CrossRefPubMed

44.

Balasa RI, Simu M, Voidazan S, Barcutean LI, Bajko Z, Hutanu A, et al. Natalizumab changes the peripheral profile of the Th17 panel in MS patients: new mechanisms of action. CNS Neurol Disord Drug Targets. 2017;16(9):1018–26. https://doi.org/10.2174/1871527316666170807130632.CrossRefPubMed

45.

Moreno Torres I, Garcia-Merino A. Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother. 2017;17(4):359–71. https://doi.org/10.1080/14737175.2017.1245616.CrossRefPubMed

46.

Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018;11:1756286418773025. https://doi.org/10.1177/1756286418773025.CrossRefPubMedPubMedCentral

47.

Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Alemtuzumab for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2018;18(3):323–34. https://doi.org/10.1080/14712598.2018.1425388.CrossRefPubMed

48.

Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154(1):69–75. https://doi.org/10.1111/imm.12902.CrossRefPubMedPubMedCentral

49.

Rehfield P, Kopes-Kerr C, Clearfield M. The evolution or revolution of statin therapy in primary prevention: where do we go from here? Curr Atheroscler Rep. 2013;15(2):298. https://doi.org/10.1007/s11883-012-0298-0.CrossRefPubMed

50.

Hashemi M, Hoshyar R, Ande SR, Chen QM, Solomon C, Zuse A, et al. Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease. Curr Mol Pharmacol. 2017;10(1):13–26. https://doi.org/10.2174/1874467209666160112123746.CrossRefPubMed

51.

Kagami S, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol. 2009;21(6):679–89. https://doi.org/10.1093/intimm/dxp037.CrossRefPubMed

52.

Steffens S, Mach F. Anti-inflammatory properties of statins. Semin Vasc Med. 2004;4(4):417–22. https://doi.org/10.1055/s-2004-869599.CrossRefPubMed

53.

Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229–43. https://doi.org/10.1161/CIRCRESAHA.116.308537.CrossRefPubMedPubMedCentral

54.

Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25(2):287–94. https://doi.org/10.1161/01.ATV.0000151647.14923.ec.CrossRefPubMed

55.

Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol. 2002;23(3):263–77. https://doi.org/10.1385/criai:23:3:263.CrossRefPubMed

56.

Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013;56(2–3):348–57. https://doi.org/10.1007/s12026-013-8409-8.CrossRefPubMed

57.

Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621–7. https://doi.org/10.1056/nejm199509073331003.CrossRefPubMed

58.

Pazik J, Ostrowska J, Lewandowski Z, Mroz A, Perkowska-Ptasinska A, Baczkowska T, et al. Renin-angiotensin-aldosterone system inhibitors and statins prolong graft survival in post-transplant glomerulonephritis. Ann Transplant. 2008;13(4):41–5.PubMed

59.

Liu WH, Xu XH, Luo Q, Zhang HL, Wang Y, Xi QY, et al. Inhibition of the rhoA/rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension. Clin Exp Hypertens. 2018;40(3):224–30. https://doi.org/10.1080/10641963.2017.1313849.CrossRefPubMed

60.

Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacol Res. 2014;88:41–52. https://doi.org/10.1016/j.phrs.2014.03.001.CrossRefPubMed

61.

Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology. 2009;127(1):18–25. https://doi.org/10.1111/j.1365-2567.2008.03011.x.CrossRefPubMedPubMedCentral

62.

Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30. https://doi.org/10.1038/343425a0.CrossRefPubMed

63.

Muller AL, Freed DH. Basic and clinical observations of mevalonate depletion on the mevalonate signaling pathway. Curr Mol Pharmacol. 2017;10(1):6–12. https://doi.org/10.2174/1874467209666160112125805.CrossRefPubMed

64.

Tricarico PM, Crovella S, Celsi F. Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link. Int J Mol Sci. 2015;16(7):16067–84. https://doi.org/10.3390/ijms160716067.CrossRefPubMedPubMedCentral

65.

Park SY, Lee JS, Ko YJ, Kim AR, Choi MK, Kwak MK, et al. Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation. Arch Pharm Res. 2008;31(2):195–204.CrossRefPubMed

66.

Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol. 2013;43(1):281–9. https://doi.org/10.1002/eji.201242566.CrossRefPubMed

67.

Forero-Pena DA, Gutierrez FR. Statins as modulators of regulatory T-cell biology. Mediat Inflamm. 2013;2013:167086–10. https://doi.org/10.1155/2013/167086.CrossRef

68.

Chalubinski M, Broncel M. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit. 2010;16(11):RA245–51.PubMed

69.

Xu H, Li XL, Yue LT, Li H, Zhang M, Wang S, et al. Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells. J Neuroimmunol. 2014;269(1–2):28–37. https://doi.org/10.1016/j.jneuroim.2014.02.002.CrossRefPubMed

70.

Reuter B, Rodemer C, Grudzenski S, Meairs S, Bugert P, Hennerici MG, et al. Effect of simvastatin on MMPs and TIMPs in human brain endothelial cells and experimental stroke. Transl Stroke Res. 2015;6(2):156–9. https://doi.org/10.1007/s12975-014-0381-7.CrossRefPubMed

71.

Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology. 2002;59(7):990–7.CrossRefPubMed

72.

Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23(5):769–75. https://doi.org/10.1161/01.ATV.0000068646.76823.AE.CrossRefPubMed

73.

Cerda A, Rodrigues AC, Alves C, Genvigir FD, Fajardo CM, Dorea EL, et al. Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients. Cardiovasc Ther. 2015;33(4):168–76. https://doi.org/10.1111/1755-5922.12126.CrossRefPubMed

74.

Shimabukuro-Vornhagen A, Zoghi S, Liebig TM, Wennhold K, Chemitz J, Draube A, et al. Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity. J Immunol. 2014;193(10):5294–305. https://doi.org/10.4049/jimmunol.1203436.CrossRefPubMed

75.

Alber HF, Frick M, Suessenbacher A, Doerler J, Schirmer M, Stocker EM, et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006;151(1):139–139.e7. https://doi.org/10.1016/j.ahj.2005.10.006.CrossRefPubMed

76.

Kubatka P, Kruzliak P, Rotrekl V, Jelinkova S, Mladosievicova B. Statins in oncological research: from experimental studies to clinical practice. Crit Rev Oncol Hematol. 2014;92(3):296–311. https://doi.org/10.1016/j.critrevonc.2014.08.002.CrossRefPubMed

77.

Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem. 2009;106(6):975–83. https://doi.org/10.1002/jcb.22092.CrossRefPubMed

78.

Link A, Selejan S, Hewera L, Walter F, Nickenig G, Bohm M. Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes. Clin Res Cardiol. 2011;100(2):147–58. https://doi.org/10.1007/s00392-010-0225-8.CrossRefPubMed

79.

Brinkkoetter PT, Gottmann U, Schulte J, van der Woude FJ, Braun C, Yard BA. Atorvastatin interferes with activation of human CD4(+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis. Clin Exp Immunol. 2006;146(3):524–32. https://doi.org/10.1111/j.1365-2249.2006.03217.x.CrossRefPubMedPubMedCentral

80.

Samson KT, Minoguchi K, Tanaka A, Oda N, Yokoe T, Okada S, et al. Effect of fluvastatin on apoptosis in human CD4+ T cells. Cell Immunol. 2005;235(2):136–44. https://doi.org/10.1016/j.cellimm.2005.08.028.CrossRefPubMed

81.

Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26(5):883–91. https://doi.org/10.1093/carcin/bgi036.CrossRefPubMed

82.

Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. 2004;172(1):85–93.CrossRefPubMed

83.

Ghittoni R, Napolitani G, Benati D, Ulivieri C, Patrussi L, Laghi Pasini F, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol. 2006;36(11):2885–93. https://doi.org/10.1002/eji.200636567.CrossRefPubMed

84.

Zhang X, Markovic-Plese S. Statins’ immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol Res. 2008;41(3):165–74. https://doi.org/10.1007/s12026-008-8019-z.CrossRefPubMed

85.

Ulivieri C, Fanigliulo D, Benati D, Pasini FL, Baldari CT. Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation. Eur J Immunol. 2008;38(10):2832–44. https://doi.org/10.1002/eji.200838278.CrossRefPubMed

86.

Lee CS, Shin YJ, Won C, Lee YS, Park CG, Ye SK, et al. Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009;33(2):107–14.PubMed

87.

Maneechotesuwan K, Kasetsinsombat K, Wamanuttajinda V, Wongkajornsilp A, Barnes PJ. Statins enhance the effects of corticosteroids on the balance between regulatory T cells and Th17 cells. Clin Exp Allergy. 2013;43(2):212–22. https://doi.org/10.1111/cea.12067.CrossRefPubMed

88.

Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008;180(10):6988–96.CrossRefPubMed

89.

Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, et al. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(12):1513–22. https://doi.org/10.1016/j.bbmt.2009.08.013.CrossRefPubMedPubMedCentral

90.

Godoy JC, Niesman IR, Busija AR, Kassan A, Schilling JM, Schwarz A, et al. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J. 2018:fj201800876R. https://doi.org/10.1096/fj.201800876R.CrossRefPubMed

91.

Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res. 2011;52(5):1023–32. https://doi.org/10.1194/jlr.M010876.CrossRefPubMedPubMedCentral

92.

Cheng SM, Lai JH, Yang SP, Tsao TP, Ho LJ, Liou JT, et al. Modulation of human T cells signaling transduction by lovastatin. Int J Cardiol. 2010;140(1):24–33. https://doi.org/10.1016/j.ijcard.2008.10.044.CrossRefPubMed

93.

Leuenberger T, Pfueller CF, Luessi F, Bendix I, Paterka M, Prozorovski T, et al. Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. PLoS One. 2014;9(7):e100871. https://doi.org/10.1371/journal.pone.0100871.CrossRefPubMedPubMedCentral

94.

Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol. 2011;271(2):455–61. https://doi.org/10.1016/j.cellimm.2011.08.015.CrossRefPubMed

95.

Meng X, Zhang K, Li J, Dong M, Yang J, An G, et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med. 2012;18:598–605. https://doi.org/10.2119/molmed.2011.00471.CrossRefPubMedPubMedCentral

96.

Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 2008;197(2):829–39. https://doi.org/10.1016/j.atherosclerosis.2007.07.031.CrossRefPubMed

97.

Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2018;15:53–8. https://doi.org/10.1038/s41582-018-0082-z.CrossRef

98.

Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS. Interferon beta-1a and beta-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol. 2018;14(2):137–53. https://doi.org/10.1080/1744666X.2018.1426462.CrossRefPubMed

99.

Montes Diaz G, Hupperts R, Fraussen J, Somers V. Dimethyl fumarate treatment in multiple sclerosis: recent advances in clinical and immunological studies. Autoimmun Rev. 2018;17:1240–50. https://doi.org/10.1016/j.autrev.2018.07.001.CrossRefPubMed

100.

Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 2017;7(7). https://doi.org/10.3390/brainsci7070078.CrossRefPubMedCentral

101.

Ciurleo R, Bramanti P, Marino S. Role of statins in the treatment of multiple sclerosis. Pharmacol Res. 2014;87:133–43. https://doi.org/10.1016/j.phrs.2014.03.004.CrossRefPubMed

102.

Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res. 2001;66(2):155–62. https://doi.org/10.1002/jnr.1207.CrossRefPubMed

103.

Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett. 1999;269(2):71–4.CrossRefPubMed

104.

Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;100(11):2671–9. https://doi.org/10.1172/JCI119812.CrossRefPubMedPubMedCentral

105.

Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, et al. Lovastatin inhibits brain endothelial cell rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17(8):905–7. https://doi.org/10.1096/fj.02-1014fje.CrossRefPubMed

106.

Bhardwaj S, Coleman CI, Sobieraj DM. Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis. Am J Health Syst Pharm. 2012;69(17):1494–9. https://doi.org/10.2146/ajhp110675.CrossRefPubMed

107.

Chen Z, Yang D, Peng X, Lin J, Su Z, Li J, et al. Beneficial effect of atorvastatin-modified dendritic cells pulsed with myelin oligodendrocyte glycoprotein autoantigen on experimental autoimmune encephalomyelitis. Neuroreport. 2018;29(4):317–27. https://doi.org/10.1097/WNR.0000000000000962.CrossRefPubMed

108.

de Oliveira DM, de Oliveira EM, Ferrari Mde F, Semedo P, Hiyane MI, Cenedeze MA, et al. Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology. 2015;23(6):343–54. https://doi.org/10.1007/s10787-015-0252-1.CrossRefPubMed

109.

Abtahi Froushani SM, Delirezh N, Hobbenaghi R, Mosayebi G. Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis. Immunol Investig. 2014;43(1):54–68. https://doi.org/10.3109/08820139.2013.825269.CrossRef

110.

Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation. 2014;11:29. https://doi.org/10.1186/1742-2094-11-29.CrossRefPubMedPubMedCentral

111.

Li Z, Chen L, Niu X, Liu J, Ping M, Li R, et al. Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol. 2012;250(1–2):9–17. https://doi.org/10.1016/j.jneuroim.2012.05.008.CrossRefPubMed

112.

Paintlia AS, Paintlia MK, Singh I, Singh AK. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol. 2008;214(2):168–80. https://doi.org/10.1016/j.expneurol.2008.07.024.CrossRefPubMedPubMedCentral

113.

Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol. 2007;8(2):172–80. https://doi.org/10.1038/ni1430.CrossRefPubMed

114.

Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol. 2004;172(2):1273–86.CrossRefPubMed

115.

Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, Barbosa E, et al. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by lovastatin. J Neurosci Res. 2004;77(1):63–81. https://doi.org/10.1002/jnr.20130.CrossRefPubMed

116.

Paintlia AS, Paintlia MK, Hollis BW, Singh AK, Singh I. Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis. Am J Pathol. 2012;181(3):993–1006. https://doi.org/10.1016/j.ajpath.2012.05.028.CrossRefPubMedPubMedCentral

117.

Paintlia AS, Paintlia MK, Singh AK, Singh I. Modulation of rho-rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-alpha-dependent mechanism. Glia. 2013;61(9):1500–17. https://doi.org/10.1002/glia.22537.CrossRefPubMedPubMedCentral

118.

Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78–84. https://doi.org/10.1038/nature01158.CrossRefPubMed

119.

Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003;197(6):725–33. https://doi.org/10.1084/jem.20021425.CrossRefPubMedPubMedCentral

120.

Paintlia AS, Paintlia MK, Singh I, Singh AK. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol. 2006;169(3):1012–25.CrossRefPubMedPubMedCentral

121.

Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006;116(4):1037–44. https://doi.org/10.1172/JCI25805.CrossRefPubMedPubMedCentral

122.

Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2015;29(4):277–91. https://doi.org/10.1007/s40263-015-0239-x.CrossRefPubMed

123.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010;16(7):848–54. https://doi.org/10.1177/1352458510369147.CrossRefPubMed

124.

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, et al. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016;22(9):1163–73. https://doi.org/10.1177/1352458515611222.CrossRefPubMed

125.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450–4. https://doi.org/10.1177/1352458509358909.CrossRefPubMed

126.

Ghasami K, Faraji F, Fazeli M, Ghazavi A, Mosayebi G. Interferon beta-1a and atorvastatin in the treatment of multiple sclerosis. Iran J Immunol. 2016;13(1):16–26.PubMed

127.

Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–21. https://doi.org/10.1016/S0140-6736(13)62242-4.CrossRefPubMed

128.

Zhang X, Tao Y, Troiani L, Markovic-Plese S. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011;187(6):3431–7. https://doi.org/10.4049/jimmunol.1100580.CrossRefPubMed

129.

Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607–8. https://doi.org/10.1016/s0140-6736(04)16205-3.CrossRefPubMed

130.

Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017;16(8):591–600. https://doi.org/10.1016/s1474-4422(17)30113-8.CrossRefPubMedPubMedCentral

131.

Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dorr J, Waiczies H, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One. 2008;3(4):e1928. https://doi.org/10.1371/journal.pone.0001928.CrossRefPubMedPubMedCentral

132.

Li XL, Zhang ZC, Zhang B, Jiang H, Yu CM, Zhang WJ, et al. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. Int Immunopharmacol. 2014;23(2):546–9. https://doi.org/10.1016/j.intimp.2014.10.004.CrossRefPubMed

133.

Kamm CP, Mattle HP, Group SS. Swiss atorvastatin and interferon Beta-1b trial in multiple sclerosis (SWABIMS)--rationale, design and methodology. Trials. 2009;10:115. https://doi.org/10.1186/1745-6215-10-115.CrossRefPubMedPubMedCentral

134.

Kamm CP, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One. 2014;9(1):e86663. https://doi.org/10.1371/journal.pone.0086663.CrossRefPubMedPubMedCentral

135.

Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390–5. https://doi.org/10.1212/01.wnl.0000319698.40024.1c.CrossRefPubMed

Titel: On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells
verfasst von: Georgios Ntolkeras
Chrysanthi Barba
Athanasios Mavropoulos
Georgios K. Vasileiadis
Efthymios Dardiotis
Lazaros I. Sakkas
Georgios Hadjigeorgiou
Dimitrios P. Bogdanos
Publikationsdatum: 09.08.2019
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 4-5/2019
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-019-09089-5

Neu im Fachgebiet HNO

15.04.2024 | Hörsturz | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells

Abstract

Neu im Fachgebiet HNO

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Hundehalter mit Luftnot: War es die Katzenminze?

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4-5/2019

Infliximab therapy for inflammatory colitis in an infant with NEMO deficiency

The prevalence of systemic sclerosis is increased among patients with alopecia areata: a population-based study

The impact of combining educational program with the improving of infrastructure to diagnose on early detection of primary immunodeficiencies in children

X-linked hyper-IgM syndrome complicated with interstitial pneumonia and liver injury: a new mutation locus in the CD40LG gene

Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia

The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system

Neu im Fachgebiet HNO

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Hundehalter mit Luftnot: War es die Katzenminze?

Update HNO